Client team was preparing to move a new candidate vaccine into global Phase III trials. The global and local medical affairs and HEOR organizations needed to understand what evidence is required to support vaccine technical committee approvals and what country-specific data gaps exist.
We identified country-specific data gaps and developed evidence generation strategies that enabled country leads to prioritize local evidence generation prior to vaccine approval meetings.